TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17459275

Group type: EXPERIMENTAL
Intervention: Curative modalities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intervention for locally advanced disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of advanced disease
Number of subjects: 0
Study: 16078671

Group type: COMPARATOR
Intervention: 50 mg sertraline daily for 12 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 50 mg sertraline daily plus 50 mg sildenafil as needed for 12 weeks
Number of subjects: 72
Study: 11953346

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 11574790

Group type: EXPERIMENTAL
Intervention: Standard care plus BAL
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 26
Study: 9133510

Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg/d
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cholesterol-lowering diet plus placebo
Number of subjects: 188
Study: 7971287

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bone scintigraphy (BSc)
Number of subjects: 102
Study: 3653876

Group type: EXPERIMENTAL
Intervention: Burkitt's lymphoma
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: non-Burkitt's lymphoma
Number of subjects: 608

Group type: COMPARATOR
Intervention: Reference diagnoses
Number of subjects: 608

Group type: COMPARATOR
Intervention: Consensus review diagnoses
Number of subjects: 608
Study: 29111919

Group type: EXPERIMENTAL
Intervention: Education-based intervention (3 sessions during the second trimester)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Education-based intervention
Number of subjects: 90
Study: 29231408

Group type: EXPERIMENTAL
Intervention: Acupoint herbal application of huiyao tongluo dingtong san
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tender point herbal application
Number of subjects: 96
Study: 24720340

Group type: EXPERIMENTAL
Intervention: Nurotron Venus cochlear implants
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cochlear Nucleus CI24
Number of subjects: 15
Study: 23684673

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 3235

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3235
Study: 20625026

Group type: EXPERIMENTAL
Intervention: Intensive behavioral weight loss program
Number of subjects: 338

Group type: COMPARATOR
Intervention: Structured health education program (control)
Number of subjects: 338
Study: 18936492

Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii (live or supernatant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii supernatant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii
Number of subjects: 0
Study: 16652049

Group type: EXPERIMENTAL
Intervention: Interruption of antiretroviral medication
Number of subjects: 36

Group type: COMPARATOR
Intervention: Continuation of antiretroviral therapy
Number of subjects: 36
Study: 12854102

Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual system of care
Number of subjects: 200
Study: 11305138

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All three anesthetics
Number of subjects: 75
Study: 8641639

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulins (IVIG) 300 mg/kg every 4 weeks for 6 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulins (IVIG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study: 1497105

Group type: EXPERIMENTAL
Intervention: Group parent training
Number of subjects: 0
Study: 29808305

Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoidal artery ligation/mucopexy (DGHAL) using THD™ (104 patients) and HAL-RAR™ (89 patients)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Circular stapled hemorrhoidopexy (CSH) using PPH-03™ (106 patients) and HEM™ (78 patients)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Doppler-guided hemorrhoidal artery ligation/mucopexy (DGHAL)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Circular stapled hemorrhoidopexy (CSH)
Number of subjects: 377
Study: 26410591

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 53
Study: 23983132

Group type: EXPERIMENTAL
Intervention: Enhanced monitoring
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 10
Study: 22018394

Group type: EXPERIMENTAL
Intervention: Structured antenatal training programme attended in mid-pregnancy
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 1193
Study: 20307824

Group type: EXPERIMENTAL
Intervention: 3-month low-moderate-intensity strength training program (2 sessions/week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 18290777

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) monotherapy for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination of ATRA and PegIFN‐alpha2a for 12 weeks
Number of subjects: 20
Study: 16595757

Group type: COMPARATOR
Intervention: Control (weight maintenance diet)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calorie restriction (25% calorie restriction of baseline energy requirements)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calorie restriction with exercise (12.5% calorie restriction plus 12.5% increase in energy expenditure by structured exercise)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Very low-calorie diet (890 kcal/d until 15% weight reduction, followed by a weight maintenance diet)
Number of subjects: 48
Study: 14614633

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (15 mg/kg/day) alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (15 mg/kg/day) plus low-dose aspirin (100 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 43
Study: 11026626

Group type: EXPERIMENTAL
Intervention: Deuterium incorporation (DI) method
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Plasma cholesterol precursor levels
Number of subjects: 14
Study: 9503879

Group type: EXPERIMENTAL
Intervention: Mixed-effect two-state model with multiplicative bivariate log-normal random effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation using Gauss-Hermite integration and Newton-Raphson procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of methodology to data from a multi-center clinical trial
Number of subjects: 0
Study: 8368986

Group type: EXPERIMENTAL
Intervention: Benadryl (diphenhydramine) 50 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hismanal (astemizole) 10 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3530647

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) at 10 cm H2O with FIO2 = 0.6
Number of subjects: 44

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP) at 0, 5, or 10 cm H2O
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Postoperative P(A‐a)O2 measurements
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Roentgenographic evidence of atelectasis
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Roentgenographic distances from hemidiaphragm to lung apex
Number of subjects: 44
Study: 30241517

Group type: EXPERIMENTAL
Intervention: 3 days of amoxicillin dispersible tablets (DT) followed by 2 days of placebo DT
Number of subjects: 2000

Group type: COMPARATOR
Intervention: 5 days of amoxicillin dispersible tablets (DT)
Number of subjects: 2000
Study: 26603771

Group type: EXPERIMENTAL
Intervention: Methylprednisolone injection
Number of subjects: 94

Group type: COMPARATOR
Intervention: Pulpotomy
Number of subjects: 94
Study: 24202666

Group type: EXPERIMENTAL
Intervention: wDP (docetaxel 35 mg/m² + cisplatin 60 mg/m²)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: wDO (docetaxel 35 mg/m² + oxaliplatin 120 mg/m²)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: wDP
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: wDO
Number of subjects: 77
Study: 23710844

Group type: EXPERIMENTAL
Intervention: email health information prescriptions (eHIP)
Number of subjects: 592

Group type: COMPARATOR
Intervention: paper health information prescriptions (pHIP)
Number of subjects: 592
Study: 20482513

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study: 18500605

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine alone
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: IV remifentanil alone
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine plus IV remifentanil
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine plus IV acetaminophen
Number of subjects: 201

Group type: COMPARATOR
Intervention: Epidural analgesia (ropivacaine)
Number of subjects: 201

Group type: COMPARATOR
Intervention: IV remifentanil
Number of subjects: 201
Study: 15820798

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (minimal stimulation protocol)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Natural-cycle IVF (control)
Number of subjects: 70
Study: 12024842

Group type: EXPERIMENTAL
Intervention: Li vasectomy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard vasectomy with bilateral incision
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 99
Study: 10527011

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 490

Group type: COMPARATOR
Intervention: No ICD therapy (Control)
Number of subjects: 490
Study: 7851588

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: leuprolide acetate (LA) plus hMG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1951102

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 18
Study: 6780105

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Number of subjects: 121

Group type: COMPARATOR
Intervention: No routine rehabilitation
Number of subjects: 121
Study: 31665927

Group type: EXPERIMENTAL
Intervention: Higher levels of diabetes distress (DD)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Higher levels of depressive symptoms (DS)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Gender
Number of subjects: 166
Study: 30165127

Group type: COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Passive Scattering Proton Therapy (PSPT)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Adaptive Planning
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Large tumors
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Adaptive Planning for Large Tumors
Number of subjects: 212
Study: 28049736

Group type: EXPERIMENTAL
Intervention: Liraglutide (4 months treatment)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calorie restriction (control)
Number of subjects: 39
Study: 25856169

Group type: EXPERIMENTAL
Intervention: High-dose caffeine (80 mg/kg i.v.)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard-dose caffeine (20 mg/kg i.v.)
Number of subjects: 74
Study: 23674932

Group type: COMPARATOR
Intervention: Intensive Lifestyle Intervention (ILI) - 1-year program (n = 59)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB) - (n = 74)
Number of subjects: 133
Study: 23120958

Group type: EXPERIMENTAL
Intervention: Oral health education at Kenyatta National Hospital (KNH)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Non-intervention group at Mbagathi district hospital (MDH)
Number of subjects: 195
Study: 18948162

Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: quetiapine IR 150 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg once daily and quetiapine IR 150 mg twice daily
Number of subjects: 0
Study: 17990061

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1 mg or 2 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1 mg or 2 mg) with motion stimulation
Number of subjects: 60
Study: 14512795

Group type: EXPERIMENTAL
Intervention: Paclitaxel monotherapy (100 mg/m2 intravenously on day 1 each week for 6 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin combination (Paclitaxel 80 mg/m2 intravenously followed by carboplatin 200 mg/m2 on day 1 each week for 6 weeks)
Number of subjects: 40
Study: 11216145

Group type: EXPERIMENTAL
Intervention: Premature delivered twins
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Premature delivered twins (born 48 hours after first twin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Term delivered twins
Number of subjects: 20
Study: 8846860

Group type: EXPERIMENTAL
Intervention: Loco-regional radiotherapy to the breast
Number of subjects: 418

Group type: COMPARATOR
Intervention: No loco-regional radiotherapy to the breast
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Incomplete local excision with radiotherapy
Number of subjects: 418
Study: 1445814

Group type: EXPERIMENTAL
Intervention: High humidity (80-93% relative humidity) at 20 and 30 degrees
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ambient humidity (50-65% relative humidity) at 20 and 30 degrees
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Temperature at ambient humidity levels (20, 23, 26, and 30 degrees)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sleeping metabolic rate and energy cost of walking and cycling
Number of subjects: 8
Study: 3846592

Group type: EXPERIMENTAL
Intervention: Cephalosporins
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cephalosporins (specific types)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Latamoxef (moxalactam)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 78

Group type: COMPARATOR
Intervention: Penicillins
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 29135601

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise at 30% maximal voluntary contraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham isometric handgrip exercise at 3% maximal voluntary contraction
Number of subjects: 40
Study: 26304156

Group type: EXPERIMENTAL
Intervention: Cisplatin-topotecan followed by carboplatin-paclitaxel (Arm 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (Arm 2)
Number of subjects: 0
Study: 25417416

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 37
Study: 22748043

Group type: EXPERIMENTAL
Intervention: Cisplatin/vinorelbine (ACT)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Observation alone (Control)
Number of subjects: 596
Study: 20202055

Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Intralesional saline (control)
Number of subjects: 135
Study: 17118570

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (50.4 Gy, 5-fluorouracil, leucovorin) with delayed surgery
Number of subjects: 291

Group type: COMPARATOR
Intervention: 5 x 5 Gy preoperative radiotherapy with immediate surgery
Number of subjects: 291
Study: 16287372

Group type: COMPARATOR
Intervention: Carbohydrate group (C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group (P)
Number of subjects: 30
Study: 11969282

Group type: EXPERIMENTAL
Intervention: Pre-operative education by multidisciplinary team prior to admission for surgery.
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual care education on admission and throughout hospital stay.
Number of subjects: 356
Study: 10333652

Group type: EXPERIMENTAL
Intervention: Tactile discrimination of the right hand (left hemisphere)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Tactile discrimination of the left hand (right hemisphere)
Number of subjects: 13
Study: 8950804

Group type: EXPERIMENTAL
Intervention: HLA‐A, ‐B, ‐DR and DQ phenotypes
Number of subjects: 217

Group type: COMPARATOR
Intervention: Comparison with Caucasoids, Negroids and Orientals
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Linkage disequilibrium analysis
Number of subjects: 217
Study: 2249011

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy (C + R group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Radiotherapy alone (R group)
Number of subjects: 151
Study: 6990761

Group type: EXPERIMENTAL
Intervention: Oral ritodrine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 70
Study: 31004732

Group type: EXPERIMENTAL
Intervention: Moderate mountain hiking and balneotherapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cultural holiday with sightseeing
Number of subjects: 139
Study: 27271517

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment recommendation implemented
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy recommendation implemented
Number of subjects: 306
Study: 25908395

Group type: EXPERIMENTAL
Intervention: Standard letter signed by general practitioner inviting patients to take a fecal occult blood test.
Number of subjects: 3422

Group type: COMPARATOR
Intervention: Standard invitation letter or standard reminder letter (Control group).
Number of subjects: 3422
Study: 24620913

Group type: EXPERIMENTAL
Intervention: Filtered Back Projection (FBP) at 75% exposure
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sinogram-affirmed iterative reconstruction at 75% exposure
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sinogram-affirmed iterative reconstruction at 100% exposure
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sinogram-affirmed iterative reconstruction at 25% and 50% exposure reduction
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sinogram-affirmed iterative reconstruction for 10 mm lesions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sinogram-affirmed iterative reconstruction for 15 mm lesions
Number of subjects: 18
Study: 22050623

Group type: EXPERIMENTAL
Intervention: Nictitating membrane removal (n = 4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nictitating membrane intact (n = 4)
Number of subjects: 8
Study: 20027411

Group type: EXPERIMENTAL
Intervention: Zyoptix LASIK (Bausch & Lomb)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Planoscan LASIK (Bausch & Lomb)
Number of subjects: 37
Study: 17937798

Group type: EXPERIMENTAL
Intervention: Mental practice embedded in daily therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapy as usual
Number of subjects: 0
Study: 15359375

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reboxetine
Number of subjects: 68
Study: 11427271

Group type: EXPERIMENTAL
Intervention: QS-21 in phosphate-buffered saline at pH 6.0 or 7.2
Number of subjects: 63

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: QS-21/PBS
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: QS-21/aluminum hydroxide
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: QS-21/4 mg/ml of polysorbate 80
Number of subjects: 63

Group type: COMPARATOR
Intervention: Aluminum hydroxide (without QS-21)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: QS-21/0.72% benzyl alcohol
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: QS-21/30 mg/ml of hydroxypropyl-beta-cyclodextrin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: QS-21/8-mg/ml of polysorbate 80
Number of subjects: 63
Study: 9507412

Group type: EXPERIMENTAL
Intervention: Nerve conduction velocity distribution (CVD) study of motor nerves (external popliteal and ulnar nerves bilaterally)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nerve conduction velocity distribution (CVD) study of sensory nerves (median nerve bilaterally)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard electrophysiological examination of motor nerves
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard electrophysiological examination of sensory nerves
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CVD study compared to standard examination
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CVD study for patients with motor and mixed subclinical neuropathy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CVD study findings unaccompanied by slowing of maximum nerve conduction velocity
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CVD study findings for sensory nerves
Number of subjects: 138
Study: 8296279

Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Curosurf
Number of subjects: 48
Study: 1523282

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clovoxamine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35